Cytomegalovirus-related complications in human hand transplantation

Transplantation

Volumn 80, Issue 4, 2005, Pages 441-447

  Schneeberger, Stefan ^a   Lucchina, Stefano ^b   Lanzetta, Marco ^b   Brandacher, Gerald ^a   Bösmüller, Claudia ^a   Steurer, Wolfgang ^a   Baldanti, Fausto ^c   Dezza, Clara ^b   Margreiter, Raimund ^a   Bonatti, Hugo ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b SAN GERARDO HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Composite tissue allograft; Cytomegalovirus; Hand transplantation; Rejection

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CIDOFOVIR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CANDIDA; CLINICAL ARTICLE; COHORT ANALYSIS; COMPOSITE GRAFT; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG MEGADOSE; EDEMA; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HAND; HAND TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; REGISTER; THUMB; TRANSPLANTATION; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GANCICLOVIR; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HAND; HAND INJURIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TACROLIMUS; TISSUE DONORS;

EID: 23944448047     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000168454.68139.0a     Document Type: Article

References (22)

1. Margreiter R, Brandacher G, Ninkovic M, et al. A double-hand transplant can be worth the effort! Transplantation 2002; 74: 85.
2. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999; 1 (Suppl 1): 8.
3. Fateh-Moghadam S, Bocksch W, Wessely R, et al. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003; 76: 1470.
4. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 1995; 9: 863.
5. Streblow DN, Kreklywich C, Yin Q, et al. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol 2003; 77: 2182.
6. Evans PC, Soin A, Wreghitt TG, et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69: 30.
7. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731.
8. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73.
9. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83.
10. Hebart H, Kanz L, Jahn G, Einsele H. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs 1998; 55: 59.
11. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742.
12. Paya C, Humar A, Dominguez E, et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
13. Schneeberger H, Aydemir S, Muller R, et al. Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival. Transpl Int 2000; 13 (Suppl 1): S354.
14. Lanzetta M, Petruzzo P, Vitale G, et al. Human hand transplantation: what have we learned? Transplant Proc 2004; 36: 664.
15. 14a. Lanzetta M, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2005; 79: 1210-1214.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
17. Jones JW, Gruber SA, Barker JH, Breidenbach WC. Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. N Engl J Med 2000; 343: 468.
18. Schneeberger S, Kreczy A, Brandacher G, et al. Steroid- and ATG-resistant rejection after forearm transplantation responds to Campath-1H. Am J Transplant 2004; 4: 1372.
19. Sageda S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
20. Barker JH, Francois CG, Frank JM, Maldonado C. Composite tissue allotransplantation. Transplantation 2002; 73: 832.
21. Hofmann GO, Kirschner MH. Clinical experience in allogeneic vascularized bone and joint allografting. Microsurgery 2000; 20: 375.
22. Lautenschlager I, Soots A, Krogerus L, et al. CMV increases inflammation and accelerates chronic rejection in rat kidney allografts. Transplant Proc 1997; 29: 802.